| Original language | English (US) |
|---|---|
| Pages (from-to) | 257 |
| Number of pages | 1 |
| Journal | American journal of ophthalmology |
| Volume | 199 |
| DOIs | |
| State | Published - Mar 2019 |
ASJC Scopus subject areas
- Ophthalmology
Access to Document
Other files and links
Cite this
- APA
- Standard
- Harvard
- Vancouver
- Author
- BIBTEX
- RIS
Diagnosis, Clinical Presentations, and Outcomes of Nocardia Endophthalmitis. / Sridhar, Jayanth; Albini, Thomas A.; Flynn, Harry W.; Silva, Ruwan A.; Young, Ryan C.
In: American journal of ophthalmology, Vol. 199, 03.2019, p. 257.Research output: Contribution to journal › Letter › peer-review
}
TY - JOUR
T1 - Diagnosis, Clinical Presentations, and Outcomes of Nocardia Endophthalmitis
AU - Sridhar, Jayanth
AU - Albini, Thomas A.
AU - Flynn, Harry W.
AU - Silva, Ruwan A.
AU - Young, Ryan C.
N1 - Funding Information: Funding/Support: The authors have no funding or grant support to disclose. The Bascom Palmer Eye Institute received funding from NIH Core Grant P30EY014801 , Department of Defense Grant # W81XWH-13-1-0048 , and a Research to Prevent Blindness Unrestricted Grant. Financial Disclosures: Jayanth Sridhar is a consultant for Alcon, Allergan, and Alimera Science. Thomas A. Albini is a consultant for Allegro Ophthalmics, Beaver Visitec, Clearside Biomedical Inc, Eyepoint Pharmaceuticals, Inc, Janssen Biotech Inc, Notal Vision, Novartis, Santen Pharmaceutical, and Valeant Pharmaceuticals. The following authors have no financial disclosures: Harry W. Flynn, Jr, Ruwan A. Silva, and Ryan C. Young. All authors attest that they meet the current ICMJE criteria for authorship. Funding Information: Funding/Support: The authors have no funding or grant support to disclose. The Bascom Palmer Eye Institute received funding from NIH Core Grant P30EY014801, Department of Defense Grant #W81XWH-13-1-0048, and a Research to Prevent Blindness Unrestricted Grant. Financial Disclosures: Jayanth Sridhar is a consultant for Alcon, Allergan, and Alimera Science. Thomas A. Albini is a consultant for Allegro Ophthalmics, Beaver Visitec, Clearside Biomedical Inc, Eyepoint Pharmaceuticals, Inc, Janssen Biotech Inc, Notal Vision, Novartis, Santen Pharmaceutical, and Valeant Pharmaceuticals. The following authors have no financial disclosures: Harry W. Flynn, Jr, Ruwan A. Silva, and Ryan C. Young. All authors attest that they meet the current ICMJE criteria for authorship.
PY - 2019/3
Y1 - 2019/3
UR - http://www.scopus.com/inward/record.url?scp=85061828317&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85061828317&partnerID=8YFLogxK
U2 - 10.1016/j.ajo.2018.10.023
DO - 10.1016/j.ajo.2018.10.023
M3 - Letter
C2 - 30545476
AN - SCOPUS:85061828317
VL - 199
SP - 257
JO - American Journal of Ophthalmology
JF - American Journal of Ophthalmology
SN - 0002-9394
ER -